Bruce Donald to offer Seminar on Computational Biology spring 2018

Bruce Donald to offer Seminar on Computational Biology spring 2018

Seminar on Computational Biology
COMPSCI 590-02 and CBB 590-02
Professor Bruce Donald

The first class meeting will be Wednesday, January 10, 1:25-3:55, in Room North 311.

"Strictly speaking, molecular biology is not a new discipline, but rather a new way of looking at organisms as reservoirs and transmitters of information. This new vision opened up possibilities of action and intervention that were revealed during the growth of genetic engineering." - Michel Morange, "A History of Molecular Biology," Harvard University Press.

Some of the most challenging and influential opportunities for Physical Geometric Algorithms (PGA) arise in developing and applying information technology to understand the molecular machinery of the cell. Recent work shows that PGA techniques may be fruitfully applied to the challenges of structural molecular biology and rational drug design. Concomitantly, a wealth of interesting computational problems arise in proposed methods for discovering new pharmaceuticals. This seminar course focuses on topics in computational biology. They will emphasize themes that unite algorithms, modelling, and experimental results. Topics will include algorithms, modeling, and experimental validation for several areas, including protein design, protein:protein interactions, structural biology, structural immunology, and structure-based drug design.

For those who have taken a class or seminar with Dr. Donald previously, this semester they will read entirely different papers, so please feel free to sign up.

Graduate students and undergraduate students are welcome in this class. In this class Dr. Donald welcomes students from diverse backgrounds: computer science, biochemistry, biology, chemistry, engineering, physics... is recommended that students be interested in the connections between computational science and the life sciences as applied to macromolecules of biological and pharmacological importance.

In this seminar course students will present both recent and classic papers from the literature, and also compile notes on these papers. This year, students will also get to use state-of-the-art molecular design software to design proteins and molecular interactions.

Class will end in plenty of time for students to attend the SBB Seminar.

The primary reading for this course will be supplied as papers to the students. While some of the background for these papers may be unfamiliar, the class is structured so that students can acquire this background while preparing to present and discuss the papers. Specifically, students will read a textbook, that is designed for this course, in order to prepare for and understand the background to present the papers. One textbook covers basic algorithms in this area of computational biology, and their applications. The second covers recent results in the field of protein design. When the weekly papers are assigned, relevant chapters of the textbooks will be assigned as area/background reading. However, student presentations will concentrate on the papers, not on presenting from the textbooks.

The first class meeting will be Wednesday January 10, 1:25-3:55, in Room North 311

Note the unusual time!

After that we will meet:
Mondays 1:25-3:55
North 311

Related Links:

Related News

Dr. Beth Sullivan and Naeema Hopkins-Kotb next to scientific poster

Summer springs into fall opportunity

Students interested in careers in genome sciences and medicine need a strong foundation of core genome sciences, technology and interdisciplinary training.
picture collage with images from four different Bass Connections Projects plus a picture of Duke Campus

Bass Connections Annual Report Out Now

Bass Connections released their

A graphical abstract of how the team uses epigenomic editing to downregulate SNCA genes

Targeted epigenome editing as ‘next generation drugs’ for Parkinson’s disease

By 2020, the Parkinson’s Foundation estimates that nearly one million people will be living with Parkinson’s disease in the U.S.